Compare Indonesia Energy Corporation Limited (INDO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Summit Therapeutics Inc — how do they compare? Indonesia Energy Corporation Limited trades at $2.79 (market cap $43.24M), while Summit Therapeutics Inc trades at $17.41 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 317.1× Indonesia Energy Corporation Limited's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Summit Therapeutics Inc for 16 Days on average.
| INDO | SMMT | |
|---|---|---|
Market Cap | $43.24M | $13.71B |
Volume | 116,953 | 6,173,057 |
Sector | Energy | Health |
52-Week High | $6.74 | $26.38 |
52-Week Low | $2.49 | $12.43 |
Typical Hold Time | 24 Days | 16 Days |
Enterprise Value | $38.18M | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.79, up 0.72% on the day, amid a bearish technical signal. The company reported a net loss of $5.10M on $2.01M revenue for 2025, with negative profit margins. Recent news highlights operational progress, including oil discovery at the K-29 well and participation in investment conferences.
Despite unanimous analyst buy ratings, INDO faces significant financial challenges with persistent losses and negative cash flow from operations. The stock's outlook hinges on successful production scaling from new wells, but execution risks and weak fundamentals present substantial downside potential for investors.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
